Vav1-dependent Rac1 activation mediates hypoxia-induced gemcitabine resistance in pancreatic ductal adenocarcinoma cells through upregulation of HIF-1α expression

Cell Biol Int. 2023 Nov;47(11):1835-1842. doi: 10.1002/cbin.12074. Epub 2023 Aug 6.

Abstract

Hypoxia has been shown to induce gemcitabine (GEM) resistance in pancreatic ductal adenocarcinoma (PDAC) cells, however, the underlying mechanisms remain to be clarified. In the present study, we investigated whether activation of Vav1/Rac1/HIF-1α axis is responsible for hypoxia-induced GEM resistance in PDAC cells. Our results showed that Rac1 activation contributed to hypoxia-induced GEM resistance in PANC-1 cells. Hypoxia treatment led to an increased expression level of Vav1, which was responsible for Rac1 activation and GEM resistance in PDAC cells. Furthermore, Rac1 mediated hypoxia-induced GEM resistance by upregulating HIF-1α in PDAC cells. Taken together, these findings suggest that hypoxia induces GEM resistance in PDAC cells by activating the Vav1/Rac1/HIF-1α signaling pathway.

Keywords: Rac1; Vav1; apoptosis; drug resistance; hypoxia; pancreatic ductal adenocarcinoma.

MeSH terms

  • Carcinoma, Pancreatic Ductal* / drug therapy
  • Carcinoma, Pancreatic Ductal* / metabolism
  • Carcinoma, Pancreatic Ductal* / pathology
  • Cell Line, Tumor
  • Drug Resistance, Neoplasm*
  • Gemcitabine*
  • Humans
  • Hypoxia
  • Pancreatic Neoplasms* / metabolism
  • Up-Regulation

Substances

  • Gemcitabine
  • HIF1A protein, human
  • RAC1 protein, human
  • VAV1 protein, human